[{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"137ec32f-5e52-4616-9b33-b322d2b339d9","acronym":"TAPISTRY","url":"https://clinicaltrials.gov/study/NCT04589845","created_at":"2021-04-08T16:52:35.237Z","updated_at":"2025-02-25T14:07:57.580Z","phase":"Phase 2","brief_title":"Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","source_id_and_acronym":"NCT04589845 - TAPISTRY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Gavreto (pralsetinib) • ipatasertib (RG7440) • belvarafenib (RG6185) • idasanutlin (RG7388) • divarasib (RG6330) • Itovebi (inavolisib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 920","initiation":"Initiation: 01/18/2021","start_date":" 01/18/2021","primary_txt":" Primary completion: 09/25/2032","primary_completion_date":" 09/25/2032","study_txt":" Completion: 09/25/2032","study_completion_date":" 09/25/2032","last_update_posted":"2025-02-17"},{"id":"e3328e0d-a58a-4276-b607-b9374b9c681f","acronym":"AcceleRET Lung","url":"https://clinicaltrials.gov/study/NCT04222972","created_at":"2021-01-18T14:26:40.385Z","updated_at":"2025-02-25T16:37:43.151Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04222972 - AcceleRET Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 223","initiation":"Initiation: 07/24/2020","start_date":" 07/24/2020","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-02-06"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"},{"id":"592ebddd-dcd6-4b4f-ad61-a8f732fba350","acronym":"ARROW","url":"https://clinicaltrials.gov/study/NCT03037385","created_at":"2021-01-17T17:13:27.011Z","updated_at":"2024-07-02T16:35:10.042Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","source_id_and_acronym":"NCT03037385 - ARROW","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET mutation • RET rearrangement","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 589","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 03/21/2024","primary_completion_date":" 03/21/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-11"},{"id":"557b19f9-7188-4df8-9db3-bfc502e77692","acronym":"AcceleRET-MTC","url":"https://clinicaltrials.gov/study/NCT04760288","created_at":"2021-02-18T22:55:15.019Z","updated_at":"2024-07-02T16:35:24.361Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","source_id_and_acronym":"NCT04760288 - AcceleRET-MTC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET • CEACAM5","pipe":" | ","alterations":" RET mutation","tags":["RET • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Gavreto (pralsetinib) • Caprelsa (vandetanib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 10/06/2027","primary_completion_date":" 10/06/2027","study_txt":" Completion: 04/12/2035","study_completion_date":" 04/12/2035","last_update_posted":"2024-01-05"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"},{"id":"ae51cabc-9160-4b76-b164-6ac35c2f8fb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04204928","created_at":"2021-01-18T20:29:03.088Z","updated_at":"2024-07-02T16:36:26.395Z","phase":"","brief_title":"Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC","source_id_and_acronym":"NCT04204928","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" EGFR • BRAF • ALK • RET • ROS1 • NTRK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • RET fusion • RET mutation","tags":["EGFR • BRAF • ALK • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • RET fusion • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gavreto (pralsetinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-08-13"},{"id":"28b971bf-ba9b-4dbc-a6e8-b8b36e9a25d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697446","created_at":"2021-01-18T14:26:45.505Z","updated_at":"2024-07-02T16:36:26.703Z","phase":"","brief_title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","source_id_and_acronym":"NCT04697446","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" RET","pipe":" | ","alterations":" RET fusion • RET positive","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Gavreto (pralsetinib)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 279","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 10/31/2021","study_completion_date":" 10/31/2021","last_update_posted":"2021-08-10"}]